First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Institut Gustave Roussy · Université Paris-Sud · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,146
total citations
- FWCI
- 112.20
- Percentile
- 100%
- References
- 29
Citations per year
Authors
22- JSJean‐Charles SoriaCorresponding
Institut Gustave Roussy, Université Paris-Sud
- DSDaniel S.W. Tan
Genome Institute of Singapore, National Cancer Centre Singapore
- RCRita Chiari
Azienda Ospedaliera di Perugia
- YWYi‐Long Wu
Guangdong General Hospital, Guangdong Academy of Medical Sciences
- LPLuis Paz‐Ares
Universidad Complutense de Madrid
Topics & keywords
Topics
Keywords
- Ceritinib
- Medicine
- Pemetrexed
- Carboplatin
- Internal medicine
- Anaplastic lymphoma kinase
- Lung cancer
- Oncology
No related works found for this paper.